Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycle® molecules, which are designed to address diseases that lack effective treatments. These fully synthetic short peptides are uniquely structured to enhance target binding with high affinity and selectivity, making them promising candidates for drug development. The company is actively conducting clinical trials for several innovative products, including toxin conjugates and immune cell agonists, while also exploring radiopharmaceutical applications. Headquartered in Cambridge, UK, with a significant presence in Cambridge, Massachusetts, Bicycle Therapeutics fosters a culture of adventure, dedication, and teamwork among its employees, emphasizing the importance of collaboration and innovation in delivering impactful therapies.